Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Summary not available.
Summary not available.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) reported strong progress as it prepares for the potential launch of roflumilast cream for plaque psoriasis, expected by July 29, 2022. The company completed enrollment for pivotal Phase 3 trials of roflumilast foam for seborrheic dermatitis and scalp psoriasis, with topline data anticipated soon. Financially, Arcutis holds ~$345 million in cash and equivalents, providing a runway into 2024. However, the company's R&D and G&A expenses surged, leading to a net loss of $64.3 million for Q1 2022.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of 135,900 restricted stock units and options for 324,200 shares to 49 new employees on May 2, 2022. This grant, made under the 2022 Inducement Plan, is designed to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, and stock options have a ten-year term with an exercise price of $21.34. Arcutis focuses on developing innovative treatments for immune-mediated dermatological conditions and has an active pipeline, including an FDA review for a new drug application.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the completion of subject enrollment in its pivotal Phase 3 ARRECTOR trial for roflumilast foam targeting scalp and body psoriasis. With 432 subjects enrolled, the trial aims to determine the foam's efficacy and safety, as scalp psoriasis affects approximately 40% of individuals with plaque psoriasis. Results are expected by late Q3 or early Q4 2022, potentially paving the way for a supplemental New Drug Application. The unique foam formulation addresses treatment challenges in sensitive areas, offering a much-needed one-daily option.
Arcutis Biotherapeutics (Nasdaq: ARQT) outlined key clinical advancements and growth strategies during its Investor Day, emphasizing the upcoming launch of topical roflumilast ahead of the PDUFA action date on July 29. The company is poised for potential revenues of $1.8 billion to $3.8 billion in the U.S. dermatology segment by 2030. Current clinical trials show promising results in conditions like plaque psoriasis and seborrheic dermatitis, while the early pipeline includes ARQ-255 for alopecia areata expected to enter the clinic in 2022.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported positive pooled results from its Phase 3 DERMIS trials for roflumilast cream, a treatment aimed at plaque psoriasis. At week 8, 40% of patients achieved Investigator Global Assessment (IGA) success compared to 7% for the vehicle. Roflumilast cream demonstrated consistent efficacy across varying psoriasis severities and was well-tolerated, with low adverse events. Interim Phase 3 open-label study results revealed sustained efficacy over 32 weeks. The FDA has filed a New Drug Application for the cream, targeting a decision date of July 29, 2022.
Arcutis Biotherapeutics (Nasdaq: ARQT) presents positive results from its Phase 2 study of roflumilast foam 0.3%, designed for seborrheic dermatitis treatment, during the 2022 American Academy of Dermatology annual meeting. The foam demonstrated a significant IGA success rate of 73.8% against 40.9% for the vehicle (p0.0001) and improved patient quality of life across emotional, symptom, and functioning domains. The pivotal Phase 3 STRATUM trial is currently enrolling patients, with topline data expected mid-2022.
Summary not available.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced an upcoming Investor Day scheduled for March 28, 2022, in Boston, MA, at 10:30 a.m. EDT. Presenters include CEO Frank Watanabe and other key executives, who will discuss the company’s strategic plans, including the launch of investigational roflumilast cream for plaque psoriasis and its applications for atopic dermatitis and seborrheic dermatitis. The event will be accessible via a live webcast, with an archive available later. Arcutis focuses on innovative solutions for immune-mediated dermatological conditions.